Is that good, or are we just throwing money into more research that is being outdone by our competitors already? What's the point?
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-5
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.89 |
Change
-0.290(5.60%) |
Mkt cap ! $75.81M | |||
| Open | High | Low | Value | Volume |
| $5.15 | $5.15 | $4.88 | $45.35K | 9.049K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $4.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.08 | 570 | 2 |
View Market Depth
| Last trade - 12.06pm 21/07/2025 (20 minute delay) ? |
| AVR (ASX) Chart |